Biotech News
MaxCyte Announces Planned CFO Transition in 2026
investors.maxcyte.com2026-05-06 14:58 EST
Company initiates search for successor ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell